Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI106059

Localization of the oxidative defect in phytanic acid degradation in patients with refsum's disease

Charles E. Mize, James H. Herndon Jr., John P. Blass, G. W. A. Milne, Charlotte Follansbee, Philippe Laudat, and Daniel Steinberg

1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Mize, C. in: PubMed | Google Scholar

1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Herndon, J. in: PubMed | Google Scholar

1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Blass, J. in: PubMed | Google Scholar

1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Milne, G. in: PubMed | Google Scholar

1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Follansbee, C. in: PubMed | Google Scholar

1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Laudat, P. in: PubMed | Google Scholar

1Molecular Disease Branch, National Heart Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Steinberg, D. in: PubMed | Google Scholar

Published June 1, 1969 - More info

Published in Volume 48, Issue 6 on June 1, 1969
J Clin Invest. 1969;48(6):1033–1040. https://doi.org/10.1172/JCI106059.
© 1969 The American Society for Clinical Investigation
Published June 1, 1969 - Version history
View PDF
Abstract

The rate of oxidation of phytanic acid-U-14C to 14CO2 in three patients with Refsum's disease was less than 5% of that found in normal volunteers. In contrast, the rate of oxidation of α-hydroxyphytanic acid-U-14C and of pristanic acid-U-14C to 14CO2, studied in two patients, while somewhat less than that in normal controls, was not grossly impaired. These studies support the conclusion that the defect in phytanic acid oxidation in Refsum's disease is located in the first step of phytanic acid degradation, that is, in the alpha oxidation step leading to formation of α-hydroxyphytanic acid.

The initial rate of disappearance of plasma free fatty acid radioactivity after intravenous injection of phytanic acid-U-14C (t½ = 5.9 min) was slower than that seen with pristanic acid-U-14C (t½ = 2.7 min) or palmitic acid-1-14C (t½ = 2.5 min). There were no differences between patients and normal controls in these initial rates of free fatty acid disappearance for any of the three substrates tested.

There was no detectable lipid radioactivity found in the plasma 7 days after the injection of palmitic acid-1-14C or pristanic acid-U-14C in either patients or controls. After injection of phytanic acid-U-14C, however, the two patients showed only a very slow decline in plasma lipid radioactivity (estimated t½ = 35 days), in contrast to the normals who had no detectable radioactivity after 2 days. Incorporation of radioactivity from phytanic acid-U-14C into the major lipid ester classes of plasma was studied in one of the patients; triglycerides accounted for by far the largest fraction of the total present between 1 and 4 hr.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1033
page 1033
icon of scanned page 1034
page 1034
icon of scanned page 1035
page 1035
icon of scanned page 1036
page 1036
icon of scanned page 1037
page 1037
icon of scanned page 1038
page 1038
icon of scanned page 1039
page 1039
icon of scanned page 1040
page 1040
Version history
  • Version 1 (June 1, 1969): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts